CRYOPRECIPITATE

ANN NYIHA
VIVIAN WANJIKU
DIANA MUTAI
 WHAT IS CRYOPRECIPITATE

• It is a blood product derived from fresh frozen plasma through a process of controlled
thawing
• It is a concentrate of cold and insoluble high molecular weight plasma proteins
• Precipitates when frozen plasma slowly thaws at 1-6 degrees
• Cryroprecipitate is primarily used to treat bleeding disorders
COMPOSITION

• Cryoprecipitate is composed of various plasma proteins including:

• Von Willebrand factor
• Fibrinogen
• Factor VIII
• Factor XIII
• Fibronectin
 PRODUCTION OF CRYOPRECIPITATE

• Collection of Fresh frozen plasma from donated whole blood or apheresis donations
• Freezing the FFP; temperature is lowered to -18 degrees Celsius or lower to preserve the stability of
plasma proteins
• Controlled thawing: the FFP is carefully thawed in a water bath at a controlled temperature
• Collection of cryoprecipitate: As the FFP thaws, the cryoprecipitate fraction begins to separate from the
remaining plasma: The cryoprecipitate is collected by carefully separating it from the supernatant
plasma: The collected cryoprecipitate is then transferred to a separate container or bag.
• Filtration and sterility check; The cryoprecipitate is typically filtered to remove any clots or impurities.
• Packaging and storage
FUNCTIONS OF CRYOPRECIPITATE

1. Fibrinogen: Fibrinogen is a key protein involved in blood clot formation. When bleeding occurs, fibrinogen is converted into
fibrin strands, forming a mesh that traps platelets and other blood cells to create a stable clot.

2. von Willebrand factor (vWF): vWF plays a crucial role in platelet adhesion and aggregation, facilitating the formation of blood
clots. It helps platelets adhere to damaged blood vessels and promotes platelet aggregation at the site of injury.

3. Factor VIII: Factor VIII, also known as antihemophilic factor, is a clotting factor necessary for the formation of a stable blood
clot. It plays a crucial role in the intrinsic pathway of the coagulation cascade and is deficient in individuals with hemophilia A.

4. Factor XIII: Factor XIII is an enzyme that strengthens and stabilizes blood clots by cross-linking fibrin strands. It enhances the
clot's resistance to fibrinolysis (breakdown of clots) and contributes to the formation of a stable clot.

5. Fibronectin: Fibronectin is a glycoprotein that helps in platelet adhesion and clot formation. It also plays a role in wound
healing and tissue repair.
 INDICATIONS FOR CRYOPRECIPITATE TRANSFUSION

1. Hypofibrinogenemia or Dysfibrinogenemia: Cryoprecipitate is commonly used in patients with low

fibrinogen levels or abnormal fibrinogen function.
2. Massive Hemorrhage: It may be administered in cases of severe bleeding or during surgical
procedures associated with significant blood loss.
3. Hemophilia A: Cryoprecipitate contains factor VIII, which is deficient in individuals with
hemophilia A. It can be transfused to raise factor VIII levels.
4. von Willebrand Disease: Cryoprecipitate contains von Willebrand factor, a protein involved in
platelet function and clot formation. It can be used to manage bleeding in patients with von
Willebrand disease.
5. Factor XIII Deficiency: Cryoprecipitate is a source of factor XIII, which is necessary for stable
fibrin clot formation. It is used in patients with factor XIII deficiency
CONTRAINDICATIONS
STORAGE